Eli Lilly's manufacturing expansion secures GLP-1 lead
Eli Lilly's massive infrastructure spending ensures it can monetize its dominant position in GLP-1 obesity treatments while funding pipeline diversification.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.